Martingale Asset Management L P Purchases 4,200 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Martingale Asset Management L P increased its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,650 shares of the biopharmaceutical company’s stock after acquiring an additional 4,200 shares during the period. Martingale Asset Management L P owned about 0.12% of Theravance Biopharma worth $552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Theravance Biopharma in the 4th quarter valued at $69,000. Teacher Retirement System of Texas bought a new position in Theravance Biopharma during the fourth quarter valued at about $103,000. XTX Topco Ltd increased its holdings in Theravance Biopharma by 34.5% during the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 5,243 shares during the last quarter. SG Americas Securities LLC raised its position in Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,349 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Theravance Biopharma by 27.6% in the fourth quarter. Wells Fargo & Company MN now owns 21,704 shares of the biopharmaceutical company’s stock valued at $204,000 after acquiring an additional 4,695 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $11.33.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This trade represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $8.40 on Friday. The stock has a market capitalization of $415.56 million, a price-to-earnings ratio of -8.32 and a beta of 0.14. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $10.90. The stock’s 50-day simple moving average is $9.18 and its 200 day simple moving average is $9.13.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The firm had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, research analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.